Scarica l'app Stockscreener
1.48
6.47%
0.09
Dopo l'orario di chiusura:
1.49
0.01
+0.68%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CTXR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.39
Aprire:
$1.59
Volume 24 ore:
10.97M
Relative Volume:
19.19
Capitalizzazione di mercato:
$25.18M
Reddito:
-
Utile/perdita netta:
$-39.14M
Rapporto P/E:
-0.2479
EPS:
-5.97
Flusso di cassa netto:
$-28.20M
1 W Prestazione:
+15.62%
1M Prestazione:
+26.50%
6M Prestazione:
+49.65%
1 anno Prestazione:
-85.63%
Intervallo 1D:
$1.39
$1.94
Intervallo di 1 settimana:
$1.22
$1.94
Portata 52W:
$0.65
$12.84
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Nome
Citius Pharmaceuticals Inc
Settore
Industria
Telefono
(908) 967-6676
Indirizzo
11 COMMERCE DRIVE, CRANFORD, NJ
Confronta CTXR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
1.48 | 22.12M | 0 | -39.14M | -28.20M | -5.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-30 | Aggiornamento | D. Boral Capital | Hold → Buy |
| 2021-11-30 | Iniziato | Maxim Group | Buy |
Citius Pharmaceuticals Inc Borsa (CTXR) Ultime notizie
Is Citius Pharmaceuticals Inc. stock positioned for long term growth - newser.com
Is Citius Pharmaceuticals Inc. (47N0) stock undervalued at current priceDividend Hike & Stepwise Trade Execution Plans - newser.com
Has Citius Pharmaceuticals Inc. found a price floorWeekly Profit Analysis & High Return Stock Watch Alerts - newser.com
Custom watchlist performance reports with Citius Pharmaceuticals Inc.2025 Geopolitical Influence & Daily Risk Controlled Trade Plans - newser.com
Citius Oncology and EVERSANA sign exclusive agreement for Q4 2025 launch of LYMPHIR - ROI-NJ
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™ - PR Newswire
Citius Pharmaceuticals (NASDAQ: CTXR) Eyes $400M Market Opportunity with LYMPHIR Launch - openPR.com
Is Citius Pharmaceuticals Inc. (47N0) stock considered safe haven2025 Growth vs Value & AI Based Buy/Sell Signal Reports - newser.com
Why Citius Pharmaceuticals Inc. stock could outperform in 2025Trade Volume Report & AI Driven Stock Reports - newser.com
Should you wait for a breakout in Citius Pharmaceuticals Inc.Weekly Stock Recap & Technical Buy Zone Confirmations - newser.com
How to manage a losing position in Citius Pharmaceuticals Inc.Rate Cut & Real-Time Volume Analysis Alerts - newser.com
Can Citius Pharmaceuticals Inc. (47N0) stock sustain breakout momentumJuly 2025 Reactions & Safe Capital Growth Tips - newser.com
How currency fluctuations impact Citius Pharmaceuticals Inc. stockJuly 2025 Summary & Expert Approved Trade Ideas - newser.com
What earnings revisions data tells us about Citius Pharmaceuticals Inc.Global Markets & Smart Swing Trading Alerts - newser.com
Short interest data insights for Citius Pharmaceuticals Inc.July 2025 Rallies & Long Hold Capital Preservation Plans - newser.com
Forecasting Citius Pharmaceuticals Inc. price range with options dataJobs Report & Weekly Consistent Profit Watchlists - newser.com
Is Citius Pharmaceuticals Inc. still worth holding after the dipJuly 2025 Retail & Risk Managed Investment Signals - newser.com
Citius in talks over Lymphir access in global markets - The Pharma Letter
Is Citius Pharmaceuticals Inc 47N0 a good long term investmentEarnings Growth Projections & High Return Capital Strategies - earlytimes.in
Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe - GuruFocus
Published on: 2025-10-06 05:51:11 - newser.com
How strong dollar benefits Citius Pharmaceuticals Inc. (47N0) stock2025 Pullback Review & Expert Approved Momentum Ideas - newser.com
Will Citius Pharmaceuticals Inc. (47N0) stock sustain bullish trend into 2025July 2025 Intraday Action & High Yield Stock Recommendations - newser.com
Can Citius Pharmaceuticals Inc. stock double in next 5 yearsJuly 2025 Outlook & Comprehensive Market Scan Reports - newser.com
How Citius Pharmaceuticals Inc. (47N0) stock reacts to Fed tighteningTrade Volume Summary & Precise Buy Zone Identification - newser.com
Why Citius Pharmaceuticals Inc. (47N0) stock benefits from AI revolutionTrade Analysis Report & Low Drawdown Trading Strategies - newser.com
Detecting price anomalies in Citius Pharmaceuticals Inc. with AITrade Risk Assessment & Weekly High Momentum Picks - newser.com
Will Citius Pharmaceuticals Inc. (47N0) stock deliver compounding returnsWeekly Profit Report & Expert Curated Trade Setup Alerts - newser.com
Strategies to average down on Citius Pharmaceuticals Inc.July 2025 Market Mood & Reliable Entry Point Alerts - newser.com
Is Citius Pharmaceuticals Inc. (47N0) stock a buy before earnings resultsJuly 2025 PreEarnings & Intraday High Probability Alerts - newser.com
Citius Pharmaceuticals Inc Azioni (CTXR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):